US FDA Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for TALZENNA® (talazoparib) in Combination with XTANDI® (enzalutamide) to Identify ...

Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx ...
The Barre-Montpelier Times Argus

U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for Itovebi™ (inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2 ...

Foundation Medicine, Inc., a global, patient-focused precision medicine company , today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne ® CDx ...
The American Journal of Managed Care

FDA Approves FoundationOne Liquid CDx as a Diagnostic Tool for BRCA-Mutated mCRPC

FoundationOne Liquid CDx can be used to identify niraparib and abiraterone acetate eligibility in patients with metastatic castration-resistant prostate cancer (mCRPC). According to the American ...
Yahoo Finance

Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test

FoundationOne Liquid CDx adds to Foundation Medicine’s genomic testing portfolio supporting Roche’s mission to deliver truly personalised healthcare Roche is committed to improve patient outcomes by ...
Nasdaq

Foundation Medicine Receives FDA Approval for FoundationOne®CDx as the Companion Diagnostic for LYNPARZA® to Identify Patients with HRR-Mutated Metastatic Castration ...

LYNPARZA was approved based on positive results from the PROfound study for which Foundation Medicine served as the Next-Generation Sequencing (NGS) partner Prostate cancer is the second most common ...
PharmiWeb

U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for TEPMETKO® (tepotinib) to Identify Patients with MET Exon 14 Skipping Alterations in ...

Foundation Medicine’s tissue and liquid biopsy tests can now be used to identify more patients eligible for treatment who could benefit from TEPMETKO®This is Foundation Medicine’s first real-world ...
The American Journal of Managed Care

FDA Approves FoundationOne CDx as Companion Diagnostic for Niraparib/Abiraterone in mCRPC

The FDA companion diagnostic designation for FoundationOne CDx may improve access to niraparib/abiraterone acetate for eligible patients with metastatic castration-resistant prostate cancer (mCRPC) ...
Times Argus

Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics

Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced plans to launch FoundationOne ® PGx, a pharmacogenetic (PGx) offering to identify genetic differences ...
BioWorld

Items Tagged with 'Foundationone CDx'

Pillar Biosciences LLC hopes to build a stronger foundation for its multi-cancer in vitro diagnostic, Oncoreveal Dx. The company filed a supplemental application for U.S. FDA premarket approval of ...
Business Wire

U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for KEYTRUDA® (pembrolizumab) to Identify Patients with Microsatellite Instability-High (MSI-H) Solid Tumors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. today announced that it received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne CDx to be used as a companion ...
Business Wire

Foundation Medicine Launches FoundationOne™

FoundationOne interrogates all genes somatically altered in human solid tumors that are validated targets for therapy or drivers of oncogenesis based on current knowledge. It reveals all classes of ...